Zoledronic acid-used to treat high levels of calcium in the blood that may be caused by certain types of cancer

Zoledronic acid (INN) or zoledronate is a bisphosphonate drug given intravenously to treat some bone diseases.

Zoledronic acid-used to treat high levels of calcium in the blood that may be caused by certain types of cancer

Zoledronic acid; Zoledronate; Zometa; Reclast

Aclasta, Blaztere INJ, Cytozol, Ledronzol, Natzold, Rokfos, Zifonate, Zobone, Zolasta, Zoldonat, Zoldria, Zoldro, Zoledron, Zolenic, Zolephos, Zoletrust, Zolic, Zolon, Zoltero, Zometa, Zorrent, Zyfoss

[1-hydroxy-2-(1H-imidazol-1-yl)-1-phosphonoethyl]phosphonic acid

Zoledronate is a bisphosphonic acid which is an inhibitor of osteoclastic bone resorption. Zoledronate is used to prevent osteoporosis and skeletal fractures, particularly in patients with cancers such as multiple myeloma and prostate cancer and also used to treat hypercalcemia of malignancy. It can also be helpful for treating pain from bone metastases.

The recommended dose is 4mg/100m over 15 min.

Multiple myeloma and prostate cancer, as well as for treating osteoporosis.

Electrolyte disturbances, anaemia; GI disturbances; ; iritis; dizziness; conjunctivitis; hypersensitivity reactions; weight loss; dyspnoeauveitis; influenza-like symptoms; myalgia; arthralgia; fever; rigors; renal impairment; taste disturbance; dry mouth; stomatitis; chest pain; cough; CNS effects; pruritus; rash; sweating; asthenia; peripheral oedema; hypertension; bradycardia.

Increased risk of hypocalcaemia with aminoglycosides and loop diuretics. Increased risk renal dysfunction with nephrotoxic agents.

Pregnancy; hypersensitivity, lactation; children.

Store at 15-30°C(59-86°F).

Molecular weight

272.0896

Molecular formula

C5H10N2O7P2

CAS number

118072-93-8

Precautions

• Assess serum creatinine before each treatment with zoledronic acid.
• Monitor serum calcium, phosphorous, magnesium, electrolytes, and renal function.
• Cardiac disease (avoid fluid overload).
• Renal impairment.
• Ensure adequate hydration throughout therapy and maintain urinary output of 2 L/day.
• Increased risk of bronchoconstriction in aspirin-sensitive patients.
• Consider dental examination with appropriate corrective action before initiating treatment in patients at risk of osteomyelitis and osteonecrosis of the jaws (e.g. infection, anaemia, pre-existing viral disease, trauma, coagulation disorders).